Summary Urokinase-type plasminogen activator (uPA) is a potentially important prognostic factor in breast cancer for identifying patients at high risk of recurrence. This retrospective study assessed two enzyme-linked immunosorbent assay (ELISA) methods measuring uPA antigen levels in 499 primary breast cancer cytosols. Both uPA methods were applied to cytosols used routinely for oestrogen (ER) and progesterone (PgR) receptor assays. uPA was determined using a classical ELISA method (Imubind; American Diagnostica) and a novel automatic immunoluminometric assay (Lia; Sangtec Medical). The uPA Imubind method revealed about twice as much uPA antigen (median 0.75 ng mg-1 protein) as the uPA Lia method (median 0.38 ng mg-1 protein). The correlation coefficient between the two methods was acceptable (r = 0.81), but the two techniques are not interchangeable. Univariate analyses confirmed the poor outcome of patients whose tumours contained large amounts of uPA, regardless of the technique used. Multivariate analyses showed that uPA Imubind and uPA Lia values were both strong independent prognostic factors.
without evidence of metastatic disease or any other malignant tumour at the time of diagnosis; (4) surgery as the first treatment; and (5) complete clinical, histological and biological information, especially concerning hormone receptors and antigen levels of uPA measured in cytosols by the two methods. All tumours were graded by a method based on the criteria of Scarff-BloomRichardson (Bloom and Richardson, 1957) . The MSBR grade is a simple rearrangement of the two nuclear scores of the SBR grade (Le Doussal et al, 1989) . Follow-up ranged from 385 days to 15 years, with a median of 6 years. A total of 235 patients (47%) underwent partial mastectomy with axillary lymph node clearance, and 263 patients (53%) had a modified radical mastectomy. Adjuvant post-operative locoregional radiation was given to 219 (44%) patients. Adjuvant chemotherapy was given to 206 patients (41%) and adjuvant hormonal therapy to 202 patients (40%) . Clinical, radiological and biological tests were performed every 3 months for the first 2 years and yearly thereafter. At the time of analysis, 151 patients (30%) had relapsed (local recurrence and/or distant metastasis), 117 (23%) had distant metastasis and 80 (16%) had died of cancer. Overall survival (OS), disease-free survival (DFS) and metastasis-free survival (MFS) were defined as the time between diagnosis and the occurrence of breast cancer related death, the first relapse (local recurrence and/or distant metastasis) and the first distant metastasis, respectively, or the end of the study. Patients who died of causes unrelated to breast cancer were considered as censored at the time of death. Hereafter, 'death' refers to breast cancer-related death.
Tissue extracts
Tumour specimens were obtained at surgery, selected by the pathologist and stored in liquid nitrogen. For extraction, tissue pieces (mean ± s.d., 0.22 g ± 0.06) were pulverized in liquid nitrogen in 10 mm Tris-HCl buffer pH 7.4 containing 1.5 mM EDTA, 0.5 mm dithiothreitol, 5 mM sodium molybdate and 10% glycerol. The suspension was centrifuged at 100 000 g at 40C for 60 min. The cytosols were aliquoted and stored in liquid nitrogen until use (maximum 6 months).
uPA Imubind assay uPA Imubind was determined using an enzyme-linked immunosorbent assay (ELISA) method (American Diagnostica, Greenwich, CT, USA). It detects uPA in the proenzyme form, the active two-chain uPA, uPA bound to its receptor (uPAR) and uPA in complex with the two inhibitors, PAI-I and PAI-2. Assays were all performed in duplicate. UPA levels were expressed in ng mg-' protein. The detection limit is 10 pg ml-1 diluted cytosol. The standard curve (sc-uPA) ranged from 0 to 1 ng ml-. Samples of pooled breast tumour cytosols were analysed for precision. The withinassay coefficient of variation (CV) is 9.2% and the between-assay CV is 11.6%.
uPA Lia assay The uPA Lia assay (uPA LIA; AB Sangtec Medical, Bromma, Sweden) (Ferno et al, 1996) is based on tubes precoated with mouse monoclonal anti-uPA antibody and a detection reagent containing monoclonal antibodies conjugated to an isoluminol derivative. It detects uPA in the proenzyme form, the active twochain uPA, uPA bound to its receptor (uPAR) and uPA in complex with the inhibitor PAI-1. Catalyst reagents that induce light emission from the bound isoluminol derivative are added automatically in the luminometer, and the light signal is read immediately for 5 s. The signal is measured in relative light units (RLUs). The amount of uPA in the cytosol is expressed as uPA ng mg-' protein; all incubations were performed in duplicate. The standard curve (HMW uPA) ranged from 0 to 40 ng ml-l. The 5 pg ml-' diluted cytosol. Pooled breast tumour cytosol extracts were analysed for precision. The within-assay CV is 3% and the between-assay CV is 8.3%.
Protein assay
The Pierce method (Wiechelman et al, 1988) was used for protein assay (mean 2.40 mg ml-'). The concentrations of reagents used in the extraction procedure do not interfere with the BCA assay. Standard bovine serum albumin, fraction V (BSA; Pierce Rockford, IL, USA) (2 mg ml-1 in 0.9% aqueous NaCl solution) was used for calibration. Samples and standards were both assayed in duplicate.
Oestrogen ( (Hilsenbeck et al, 1996) method, which chooses the cut-off points that minimize the P-value relating the variables to outcome measure. The search was done within a selection interval defined by excluding the 5% smallest and largest values of the variables as potential cut-off points. Because of the well-known problem of multiple testing, the observed minimum P-value was corrected (Hilsenbeck et al, 1996) . Differences in the distribution of characteristics between patient subgroups were analysed using the chi-square test. Actuarial OS, DFS and MFS rates were computed using the method of Kaplan and Meier (1958) and compared using the log rank test (Peto et al, 1977) . Multivariate analyses based upon the Cox proportional hazards model (Cox, 1972) were performed to identify the most significant factors related to OS, DFS and MFS. A significance level of 5% was chosen as the criterion for entering factors in the Cox model. The results of the multivariate analyses are expressed in terms of relative risks (RR) derived from the estimated regression coefficients along with their 95% confidence interval (CI).
RESULTS
Comparison of the two uPA assay methods Average uPA x 100 by two techniques Figure 2 Difference against mean for uPA data. d= difference in uPA (x 100); s = standard deviation of the differences (x 100) to 2.81 ng mg-' protein in the Lia method (median 0.38; 32 mean ± s.d. 0.53 ± 0.46). Figure 1 shows the scatter plot of the data, the plot of the regression line and the line of equality on which all points would lie if the two methods gave exactly the same reading every time. The correlation coefficient between the two methods was r = 0.81 (P < 0.0001). This coefficient measures the strength of the relation between the two ELISAs, not the agreement between 372 them. Perfect agreement is only obtained if the points in Figure 1 lie along the line of equality, but a perfect correlation is obtained if the points lie along the regression line. This was not the case in this study, as not all the data points clustered near either of the two lines. A plot of the differences between uPA Lia and uPA Imubind values against their mean may be more informative. Figure 2 displays the relative lack of agreement between the two assays. This lack of agreement can be summarized by computing the bias, estimated by the mean difference (d x 100) and the standard deviation of the differences (s x 100 In uPA Imubind, the minimum P-value was obtained at a cut-off of 1.84 ng mg-' protein when failure was taken as death, metastasis or relapse. The corrected P-value reached a value of < 0.0001, whatever the end point for failure, and when the range of possible cut-off points was restricted to the interval between the 5% and 95% quantiles of the uPA Imubind value. The same analysis was used to set the cut-off points for uPA Lia at 0.20 ng mg-' protein and 1.14 ng mg-' protein, with a corrected P-value of < 0.0001, whatever the end point for failure.
Relation between uPA Imubind, uPA Lia and other patients characteristics (Table 1) Whatever the technique, there was no significant link between the level of uPA and age or menopausal status. The uPA imubind value was not related to ER status, but the majority of tumours (76%) with uPA Lia < 1.14 ng mg-' protein were ER+. Tumours with high uPA values (Imubind > 1.84 or uPA Lia > 1.14) were more often PgR-. Univariate analyses (Table 2) Age and menopausal status were not significantly related to any of the three outcomes. Overall survival was influenced by ER status, but there was no significant difference in DFS or MFS. However, all the remaining factors seemed to affect OS, DFS and MFS when examined individually. In particular, high levels of uPA Imubind (> 1.84) and uPA Lia (> 1.14) were significantly associated with poorer overall survival and shorter relapse-free or metastasis-free survival. Figure 3 displays the survival curves of uPA determined by the two techniques. There are significant differences between curves 1 (uPA Imubind < 1.84) and 2 (uPA Imubind > 1.84) (P <0.0001), 3 (uPA Lia <0.20) and 4 (uPA Lia [0.20-1.14]) (P<0.001), and between curves 4 and 5 (uPA Lia> 1.14) (P < 0.00001), whatever the outcome.
Multivariate analyses
All the variables listed in 
DISCUSSION
Tumour invasion, which is associated with destruction of the basement membrane and subcellular matrix (Duffy et al, 1987) , appears to be caused by the coordinated action of proteases secreted by malignant cells and the stroma. Urokinase and its inhibitors have been proposed as new prognostic factors in breast cancer (Duffy et al, 1990; Janicke et al, 1990; Foekens et al, 1992; Spyratos et al, 1992; Bouchet et al 1994; Foekens et al, 1995) . However, their use for this purpose can only be envisaged once the results obtained with different assay methods have been compared. The prognostic value of uPA assay by the Imubind method has been demonstrated (Foekens et al, 1992; Janicke et al, 1991 Janicke et al, , 1994 . The aim of our work was to test a new automated ELISA Ferno et al (1994 Ferno et al ( , 1996 using the same method. In our study, the median value obtained in the Lia method was below that obtained in the Imubind method, confirming previous reports. There was a good correlation between the two methods, but the correlation coefficient is not a reliable basis for demonstrating the equivalence of two methods (Bland and Altman, 1986) . UPA values depend on the source and composition of the ELISA kit. Commercial antibodies have different specificities and affinities for the multiple molecular forms of urokinase, i.e. the single chain of the proenzyme (pro-uPA), the low molecular weight chain (LMW-uPA) and the high molecular weight chain (HMW-uPA). In addition, pro-uPA and HMW-uPA can be complexed to the uPA receptor (uPAR). HMW-uPA, LMW-uPA and receptor-bound uPA (uPA-uPAR) can also be complexed to the two main inhibitors of uPA (PAI-I and PAI-2). Thus, the uPA present in cytosols occurs in a variety of structures and molecular weights. The antibodies provided with the two assay kits also have different compositions (Table 4) . It is not, therefore, surprising that the observed antigen level differs when measured in the same cytosol extract, especially as the proteolytic cascade involves proenzymes and enzymes, receptors, inhibitors and antibodies with different specificities.
We used the approach of Hilsenbeck and Clark (1996) to choose the cut-offs; consequently, uPA Imubind values were dichotomized, while uPA Lia values were divided into three groups. The positions of the curves in Figure 3 justify this choice. For example, 75% of the 51 cases in group 5 (uPA Lia > 1.14) were included in group 2 (uPA Imubind > 1.84), and 22 (81%) out of the 27 patients with metastases in group 5 (uPA Lia > 1.14)
were included in group 2 (uPA Imubind > 1.84). Whatever the method (Imubind or Lia) and irrespective of the cut-offs we determined, respectively 15% and 10% of patients with high uPA values had a poor prognosis. The corresponding proportions of patients were higher (26%, 32% and 33% respectively) in the studies by Janicke et al (1990) , Foekens et al (1992) and Ferno et al (1996) . These differences can be explained by inequalities in the size of the populations studied and in the median follow-up periods (12.5 months, 48 months and 42 months respectively; 72 months in our study).
In the multivariate analyses, the predictive value of uPA remained high and independent of conventional predictive factors, regardless of the assay method (Imubind or Lia). However, high uPA Lia values were chiefly associated with shorter disease-free survival and metastasis-free survival in the overall population. In the subgroup of patients free of lymph node involvement, a high uPA Lia value was the only important adverse prognostic factor for OS, DFS and MFS. These results support those of Kute et al (1994) and Janicke et al (1993) .
Automated urokinase assay by the Lia method is thus feasible, and the predictive value of this marker is valid regardless of the method used. Whether one or several markers should be used to detect tumour invasion remains to be settled. Imubind ELISA methods for uPA, uPAR and the two inhibitors (PAI-I and PAI-2) are being assessed. It is probable that two or more markers will have to be combined to obtain a reliable prognostic score in breast cancer. Assay techniques for markers of metastatic disease must be perfectly standardized Janicke et al, 1994; Romain et al, 1995; Benraad et al, 1996; Bouchet et al, 1996; R0nne et al, 1995) if they are to be of use for diagnosis and the decision to give adjuvant therapy.
